Randomized study on hemoglobin response in iron-deficient anemic patients with solid maglignancies receiving epoetin alfa (rHuEPO) in combination with either oral or parental iron supplementation during treatment with non-platinum containing chemotherapy.
Completed
- Conditions
- IJzerdeficiente anemische patiënten met solide tumoren
- Registration Number
- NL-OMON26767
- Lead Sponsor
- VU medisch centrum
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 34
Inclusion Criteria
1. Confirmed diagnosis of a solid malignancy and planned to receive further non-platinum containing chemotherapy for at least 12 weeks;
2. Hb ¡Ü7.5 mmol/L at any time during chemotherapy;
Exclusion Criteria
1. MCV <80fL and MCHC <19.5 mmol/L;
2. MCV > 100fL;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Increase in Hb.
- Secondary Outcome Measures
Name Time Method umber of required blood transfusions, total dose of administered rHuEPO.